BOLEO-5: A phase II study of everolimus and exemestane combination in Chinese postmenopausal women with ER+/HER2- advanced breast cancer

Shuai Z.1,2, Qing-Wen Dong1,3,4, Xin-Hong Shu1,2, Feng Li1,2, Feng Jiang1,2, Zhao Q.1

1. The University of Shanghai for Traditional Chinese Medicine; 2. Shanghai University of Medicine and Health Sciences, Shanghai, China; 3. Shanghai Jiao Tong University Affiliated Sixth People's Hospital; 4. Shanghai Longhua Hospital, Shanghai Jiao Tong University School of Medicine.

INTRODUCTION

• Combination therapies have revolutionized the treatment of advanced breast cancer. However, the optimal treatment strategy remains elusive due to the diversity in tumor biology and the presence of acquired resistance.

• The BOLERO-5 study was designed to assess the safety, tolerability, and efficacy of the combination of everolimus (EVE) and exemestane (EXE) in postmenopausal women with ER+/HER2- advanced breast cancer.

RESULTS (CONCLUSIONS)

- Combination EVE and EXE is a safe and efficacious treatment option for postmenopausal women with ER+/HER2- advanced breast cancer.

- The combination may provide a potential treatment option for patients who have progressed on aromatase inhibitors.

- Further studies are needed to confirm the clinical benefit of this combination.

ACKNOWLEDGMENTS

The authors would like to acknowledge Miguel Izquierdo, Woody Tang, and Declan McCarthy (BSc, Novartis Ireland Ltd) for medical writing assistance. The authors would like to acknowledge Miguel Izquierdo, Woody Tang, and Declan McCarthy (BSc, Novartis Ireland Ltd) for medical writing assistance. The authors would like to acknowledge Miguel Izquierdo, Woody Tang, and Declan McCarthy (BSc, Novartis Ireland Ltd) for medical writing assistance. The authors would like to acknowledge Miguel Izquierdo, Woody Tang, and Declan McCarthy (BSc, Novartis Ireland Ltd) for medical writing assistance.